When your body “rejects” a stent, it doesn’t work quite like organ rejection. Instead, your immune system and blood vessels react to the stent as a foreign object, triggering either a gradual tissue buildup that re-narrows the artery or, less commonly, a sudden blood clot that blocks it. These two problems, called in-stent restenosis and stent thrombosis, are the main ways a stent can fail, and they feel different, happen on different timelines, and require different responses.
Why Your Body Reacts to a Stent
Placing a stent injures the artery wall. Your body treats this the same way it treats any wound: it sends immune cells to the site and begins building new tissue to heal the damage. The problem is that this healing response can overshoot. Smooth muscle cells in the artery wall, normally quiet and contractile, shift into a different mode. They start migrating toward the inner surface of the artery, multiplying, and producing structural material that thickens the vessel wall. This process, called neointimal hyperplasia, is the primary reason stents narrow again over time.
The migration of these muscle cells into the stent area starts within days of the procedure. Inflammation plays a central role. White blood cells, particularly a type called monocytes, are recruited to the injury site through chemical signals. Platelets that stick to the damaged area act as a landing pad for these immune cells. The number of inflammatory cells found in stented tissue directly correlates with how likely the artery is to narrow again. Essentially, the stronger your body’s inflammatory response to the stent, the greater the risk of problems down the road.
Gradual Narrowing vs. Sudden Clotting
Stent failure takes two distinct forms, and the difference matters because one develops slowly and the other can become a medical emergency within minutes.
In-stent restenosis is the gradual process. Over weeks to months, tissue grows through and over the stent’s metal mesh, slowly choking off blood flow. With older bare-metal stents, this tissue is rich in smooth muscle cells packed into a gel-like structural matrix. With newer drug-eluting stents (which release medication to slow tissue growth), the regrowth contains fewer muscle cells but can develop its own form of atherosclerosis, sometimes called neoatherosclerosis, where the new tissue itself develops fatty deposits and even calcification.
Stent thrombosis is far more abrupt. A blood clot forms inside the stent, potentially cutting off blood flow entirely. Clot material pulled from these events shows a mix of platelets, fibrin (the protein that forms the clot’s scaffold), and inflammatory white blood cells. Stent thrombosis is classified by when it happens: acute (within 24 hours of placement), subacute (1 to 30 days), late (1 month to 1 year), and very late (beyond 1 year). The acute and subacute forms are most common and often tied to the procedure itself or to stopping blood-thinning medications too early.
Interestingly, both problems can share a root cause. High-resolution imaging inside arteries has shown that neoatherosclerosis within the stented area acts as a common pathway for both clotting and gradual narrowing in cases of late stent failure.
How Common Is It?
Modern drug-eluting stents have dramatically reduced failure rates compared to bare-metal stents, but they haven’t eliminated the problem. In large vessels, restenosis rates with drug-eluting stents run around 17%. In smaller arteries, rates climb to roughly 39%, because smaller vessels are more prone to re-narrowing. Bare-metal stents, still used in some situations, have significantly higher restenosis rates overall. Stent thrombosis is rarer but more dangerous when it occurs.
Symptoms to Watch For
Many people with in-stent restenosis have no symptoms at all, which is part of what makes it tricky. When symptoms do appear, they typically mirror the original heart disease that led to the stent in the first place. Chest pressure or discomfort brought on by physical activity is the most characteristic sign. You might also notice shortness of breath, unexplained fatigue or weakness, dizziness, nausea, cold sweats, heart palpitations, or pain in your shoulder or arm.
Stent thrombosis tends to announce itself more dramatically, often resembling a heart attack with sudden, severe chest pain. If you’ve had a stent placed and develop any return of chest discomfort, arm or shoulder pain, cold sweats, shortness of breath, or new fatigue, those warrant a call to your doctor promptly.
Who Is Most at Risk
Certain health conditions consistently raise the odds of stent failure. Diabetes is one of the strongest independent risk factors. A meta-analysis of 20 randomized trials found that people with diabetes have a significantly higher risk of restenosis regardless of blood sugar control, how long they take blood thinners, or which artery was treated. The chronic inflammation that accompanies diabetes appears to fuel the tissue overgrowth process.
Chronic kidney disease also increases risk substantially, with the highest rates seen in patients on dialysis. Kidney disease is linked not just to more restenosis overall but specifically to the development of neoatherosclerosis within the stent, where the regrown tissue develops its own fatty or calcified deposits. Even mildly reduced kidney function is associated with this pattern.
High blood pressure matters too. Patients with normal blood pressure at the time of stent placement have about a 24% lower risk of restenosis compared to those with hypertension. Smoking raises risk through multiple pathways: it promotes clotting, damages blood vessel walls, increases the tissue overgrowth response, and can even cause the stent struts to sit improperly against the artery wall. High cholesterol, obesity, and having stents in small or complex arteries also increase the likelihood of problems. Receiving multiple overlapping stents or having a stent that wasn’t fully expanded during placement adds procedural risk on top of biological risk.
How Stent Failure Is Diagnosed
If your doctor suspects your stent has narrowed or clotted, the workup typically involves imaging of the stented artery. A coronary angiogram (where dye is injected and X-rays taken) can show whether the stent is open. For a more detailed look, two tools are used inside the artery itself. Intravascular ultrasound provides a cross-sectional view of the vessel and stent. Optical coherence tomography, which uses light instead of sound, offers even higher resolution and is considered the gold standard for detecting neoatherosclerosis within a stent.
Doctors also use pressure measurements inside the artery to determine whether a narrowing is actually limiting blood flow enough to cause problems, since not every degree of tissue regrowth needs treatment.
Treatment Options After Stent Failure
When a stent does fail, several options exist depending on the type and severity of the problem. The most common approach is another catheter-based procedure. This can involve inflating a balloon inside the narrowed stent to push the tissue back, sometimes using a drug-coated balloon that delivers medication directly to the site to inhibit further regrowth. Another option is placing a second drug-eluting stent inside the first one, though this adds another layer of metal and another surface for the body to react to.
For more complex cases, particularly those involving heavy calcium deposits in the regrown tissue, specialized tools can shave or break apart the obstructing material before treating the area. Bypass surgery is also an option and, in at least one study, produced notably better outcomes. Patients who underwent bypass after stent failure had a major complication rate of 12.5% over two years of follow-up, compared to 36.5% for those treated with another catheter-based procedure. Patients who received medication alone without any repeat procedure fared worst, with a 73.3% rate of major cardiac events.
Long-Term Outlook
Stent failure is a serious but manageable problem. In a study following patients for a median of two years after treatment for in-stent restenosis, about 38% experienced a major cardiac event during that period. Roughly 1 in 5 needed another procedure on the same spot, at an average of about two years after the initial retreatment. These numbers reflect the reality that once a stent has failed, the underlying biology that caused the problem hasn’t gone away, and the artery remains a higher-risk site.
Preventing stent failure starts with the medications prescribed after the procedure. Current guidelines recommend taking two blood-thinning medications (dual antiplatelet therapy) for 6 months after receiving a drug-eluting stent for stable heart disease, or 12 months if the stent was placed during treatment for a heart attack or acute coronary syndrome. Stopping these medications early is one of the most avoidable causes of stent thrombosis. Managing diabetes, blood pressure, cholesterol, and quitting smoking all meaningfully reduce the risk of your body’s healing response turning into a problem inside the stent.